Galapagos, J&J, Merck deal

Galapagos' BioFocus service division received a €1.6 million ($2.3 million) milestone payment from Johnson & Johnson's Janssen Pharmaceutica N.V. subsidiary under a January 2008 deal to discover and validate new cancer targets. The payment was triggered by BioFocus' development of advanced cellular assays and identification and validation of new cancer targets. BioFocus is eligible for up to an additional €4.5 million ($6.5 million) in milestones (see BioCentury, Jan. 7, 2008). ...